AI assistant
Xvivo Perfusion — Remuneration Information 2020
Mar 25, 2020
3130_rns_2020-03-25_7d4b8275-0598-4651-9e0a-6f8a2de7bb94.pdf
Remuneration Information
Open in viewerOpens in your device viewer
Press release March 25, 2020 Gothenburg
The Nomination Committee proposes unchanged Board remuneration adjusted
Due to the situation with the corona pandemic, XVIVO Perfusion's Nomination Committee, and the shareholders who have appointed the members in the Nomination Committee, has decided to withdraw the proposal that XVIVO Perfusion's Annual General Meeting on March 31, 2020 approves an increase in Board remuneration (item 12 on the agenda). Instead, the Nomination Committee, and the shareholders who have appointed the members in the Nomination Committee, proposes unchanged Board remuneration compared to 2019. The Nomination Committee's other proposals for the Annual General Meeting remain unchanged.
March 25, 2020 Gothenburg XVIVO Perfusion AB (publ)
For further information, please contact Christoffer Rosenblad, CFO, +46 735 192159, [email protected] Magnus Nilsson, CEO, +46 31 788 21 50, [email protected]
XVIVO Perfusion AB (publ) is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
_________________________________________________________________________________________________________________
_______________________________________________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: +46 31 788 21 50. Fax: +46 31 788 21 69. E-mail: [email protected]. Website: www.xvivoperfusion.com
This information is information that XVIVO Perfusion AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on March 25, 2020 at 10:50 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.